Pancrelipase + Pancrelipase
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis
Trial Timeline
Oct 23, 2019 → Jul 11, 2022
NCT ID
NCT03924947About Pancrelipase + Pancrelipase
Pancrelipase + Pancrelipase is a approved stage product being developed by AbbVie for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03924947. Target conditions include Cystic Fibrosis.
What happened to similar drugs?
20 of 20 similar drugs in Cystic Fibrosis were approved
Approved (20) Terminated (7) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03924947 | Approved | Completed |
Competing Products
20 competing products in Cystic Fibrosis